PVLA
Palvella Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$157.24
+1.14%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−40.3x
Market Cap
$2.27B
MomentumView details →
1D Return
+1.14%
YTD Return
+48.85%
RSI (14)
57.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−40.3x
Market Cap
$2.27B
RSI (14)
57.3
MomentumView details →
1D Return
+1.14%
YTD Return
+48.85%
SummaryUpdated Jun 1, 2026
Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company founded in 2015 and based in Wayne, Pennsylvania. The company specializes in developing novel therapies for patients with serious and rare genetic skin diseases. Since its inception, Palvella has focused on advancing its lead product candidate through clinical trials, with a particular emphasis on treating conditions driven by the mTOR (mechanistic target of rapamycin) pathway. The company went public in 2015 and continues to operate as a development-stage biotechnology firm without commercial revenue.
Similar companies
Latest newsMore news →
Palvella Therapeutics completed the rolling submission of a New Drug Application to the FDA for QTORIN rapamycin for the treatment of microcystic lymphatic malformations.5d agoPalvella Therapeutics raised $230 million through an equity offering to fund commercialization and pipeline expansion.17d agoPalvella Therapeutics announced it is on track to complete its NDA submission for QTORIN rapamycin in microcystic lymphatic malformations during the second half of 2026, with potential FDA approval targeted for the first half of 2027.30d ago